Triple Negative Breast Cancer: Next-Generation Sequencing for Target Identification.

Jonathan D Marotti, Francine B de Abreu, Wendy A Wells, Gregory J Tsongalis,

The American journal of pathology, July 23, 2017

Our ability to now study disease at the most fundamental molecular level has led to a reclassification of human cancers into numerous subtypes that vary in disease progression and response to therapy. Like most solid tumors, breast cancer is a heterogeneous disease with considerable variation in histological and biological features. Triple negative breast cancer (TNBC) is a subtype of breast cancer in which estrogen receptor and progesterone receptor are not expressed, and human epidermal growth factor receptor 2 is not amplified or overexpressed. Data derived from highly complex molecular technologies, such as microarrays and next-generation sequencing, have identified gene expression and somatic mutation profile subsets of TNBC that more accurately reflect biological behavior and may lead to further effective therapeutic targets, better prognosis, and improved outcomes. Herein, we will review the genomic findings of TNBC and discuss current efforts in precision medicine as they relate to TNBC.

Copyright © 2017. Published by Elsevier Inc.

Pubmed Link: 28734944

DOI: 10.1016/j.ajpath.2017.05.018